Emergent BioSolutions (EBS) Operating Expenses (2011 - 2026)

Emergent BioSolutions' Operating Expenses history runs 16 years deep, the most recent figure standing at $145.6 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 15.5% year-over-year to $145.6 million; the TTM figure through Mar 2026 stood at $616.1 million (down 42.1% YoY), while the FY2025 annual figure was $642.8 million, down 44.22% from the prior year.
• Operating Expenses was $145.6 million for Q1 2026 at Emergent BioSolutions, down from $176.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $630.8 million in Q2 2023 to a low of $139.3 million in Q2 2025.
• Historically, Operating Expenses has averaged $294.3 million across 5 years, with a median of $285.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 100.44% in 2023, then plunged 69.6% in 2025.
• A 5-year view of Operating Expenses shows it stood at $385.5 million in 2022, then declined by 16.89% to $320.4 million in 2023, then sank by 36.27% to $204.2 million in 2024, then slipped by 13.52% to $176.6 million in 2025, then dropped by 17.55% to $145.6 million in 2026.
• The last three Operating Expenses figures came in at $145.6 million (Q1 2026), $176.6 million (Q4 2025), and $154.6 million (Q3 2025), per Business Quant data.